ATTR treatment landscape heats up as clinical progress gathers pace

It has been a busy period for the amyloidosis treatment field. In April, Danish drugmaker Novo Nordisk (NOV: N) received US Food and Drug Administration (FDA) Fast Track designation for coramitug, its investigational treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). In March, UK biotech company Immutrin raised £65 million ($87 million) in a Series A round to advance its amyloidosis antibody program.